Recent developments in the neuropharmacology of schizophrenia

A. C. Lahti, C. A. Tamminga

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Recent developments in the neuropharmacology of schizophrenia are discussed. Research in the pathophysiology of schizophrenia has enhanced our understanding of the illness and contributed to the development of new drug therapies. With magnetic resonance imaging and positron emission tomographic scans, we are able to examine the structure and function of the brain in living schizophrenic patients. Molecular biologic techniques have been used to identify several types of dopamine receptors; these may play a key role in the pathogenesis of schizophrenia. New drug therapies have been developed that target specific receptors in the brain. Antagonists of dopa-mine and serotonin receptors were developed on the basis of the discovery that dopaminergic and serotonergic systems in the mammalian central nervous system functionally interact; balanced antagonism of these receptors may provide an enhanced antipsychotic effect.

Original languageEnglish (US)
JournalAmerican Journal of Health-System Pharmacy
Volume52
Issue number3 SUPPL. 1
StatePublished - 1995

Fingerprint

Neuropharmacology
Schizophrenia
Drug Therapy
Dihydroxyphenylalanine
Serotonin Receptors
Dopamine Receptors
Brain
Antipsychotic Agents
Central Nervous System
Magnetic Resonance Imaging
Electrons
Research

ASJC Scopus subject areas

  • Leadership and Management
  • Pharmaceutical Science

Cite this

Recent developments in the neuropharmacology of schizophrenia. / Lahti, A. C.; Tamminga, C. A.

In: American Journal of Health-System Pharmacy, Vol. 52, No. 3 SUPPL. 1, 1995.

Research output: Contribution to journalArticle

@article{890b7d45b1bd4625bf47132d5d1518d6,
title = "Recent developments in the neuropharmacology of schizophrenia",
abstract = "Recent developments in the neuropharmacology of schizophrenia are discussed. Research in the pathophysiology of schizophrenia has enhanced our understanding of the illness and contributed to the development of new drug therapies. With magnetic resonance imaging and positron emission tomographic scans, we are able to examine the structure and function of the brain in living schizophrenic patients. Molecular biologic techniques have been used to identify several types of dopamine receptors; these may play a key role in the pathogenesis of schizophrenia. New drug therapies have been developed that target specific receptors in the brain. Antagonists of dopa-mine and serotonin receptors were developed on the basis of the discovery that dopaminergic and serotonergic systems in the mammalian central nervous system functionally interact; balanced antagonism of these receptors may provide an enhanced antipsychotic effect.",
author = "Lahti, {A. C.} and Tamminga, {C. A.}",
year = "1995",
language = "English (US)",
volume = "52",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "3 SUPPL. 1",

}

TY - JOUR

T1 - Recent developments in the neuropharmacology of schizophrenia

AU - Lahti, A. C.

AU - Tamminga, C. A.

PY - 1995

Y1 - 1995

N2 - Recent developments in the neuropharmacology of schizophrenia are discussed. Research in the pathophysiology of schizophrenia has enhanced our understanding of the illness and contributed to the development of new drug therapies. With magnetic resonance imaging and positron emission tomographic scans, we are able to examine the structure and function of the brain in living schizophrenic patients. Molecular biologic techniques have been used to identify several types of dopamine receptors; these may play a key role in the pathogenesis of schizophrenia. New drug therapies have been developed that target specific receptors in the brain. Antagonists of dopa-mine and serotonin receptors were developed on the basis of the discovery that dopaminergic and serotonergic systems in the mammalian central nervous system functionally interact; balanced antagonism of these receptors may provide an enhanced antipsychotic effect.

AB - Recent developments in the neuropharmacology of schizophrenia are discussed. Research in the pathophysiology of schizophrenia has enhanced our understanding of the illness and contributed to the development of new drug therapies. With magnetic resonance imaging and positron emission tomographic scans, we are able to examine the structure and function of the brain in living schizophrenic patients. Molecular biologic techniques have been used to identify several types of dopamine receptors; these may play a key role in the pathogenesis of schizophrenia. New drug therapies have been developed that target specific receptors in the brain. Antagonists of dopa-mine and serotonin receptors were developed on the basis of the discovery that dopaminergic and serotonergic systems in the mammalian central nervous system functionally interact; balanced antagonism of these receptors may provide an enhanced antipsychotic effect.

UR - http://www.scopus.com/inward/record.url?scp=0028899414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028899414&partnerID=8YFLogxK

M3 - Article

C2 - 7749964

AN - SCOPUS:0028899414

VL - 52

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - 3 SUPPL. 1

ER -